Skip to main content
. 2022 Mar 24;15:261–275. doi: 10.2147/PGPM.S356326

Figure 2.

Figure 2

Prognosis analysis of DNTTIP1/2 mRNA expression in Pan-Cancers. (A and B) Prognosis analysis of DNTTIP1/2 in Pan-Cancers. (C) Kaplan-Meier survival analysis based on The Cancer Genome Atlas (TCGA)-Low-grade gliomas (LGG). (D) The relationship between DNTTIP1/2 expression status and clinicopathological characteristics in LGG. *P < 0.05, **P < 0.01, ***P < 0.001.

Abbreviation: NS, not significant.